Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension
Select a country to see country specific content
Pulmonary Hypertension (PH)

Pulmonary Hypertension (PH) is a serious and progressive group of conditions with various causes and no cure. There are five groups of PH, as defined by the World Health Organization (WHO), and they are characterized by increased blood pressure in the lungs.

Janssen’s focus has been on a specific, rare form of PH (WHO Group 1) called pulmonary arterial hypertension (PAH), but our research covers all groups of PH.

Janssen & Pulmonary Hypertension (PH)

In June 2017, Actelion became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. We have made PH a ‘therapeutic area of focus’ and are committed to maintaining and building on the leadership position that Actelion has built in this important disease area.

At Janssen, we are spearheading a new era for PH, working to transform the disease into a long-term manageable condition, so that patients can live a normal life. Supported by Actelion’s 20-year heritage of pioneering innovation, we are working to reach more patients and aim to help tackle the diagnosis gap that is delaying access to the care that patients need.

We want to use our full range of resources to tackle PH. From investment in research and development to innovation in medical devices and diagnostics, our commitment to building an innovative drug development pipeline is real. We're focused not only on how we treat PH but on a broader spectrum of goals for the PH community. That includes enhancing patient care, as well as advocating and educating to facilitate faster diagnosis.

PH Human

PH Human

References

National Psoriasis Foundation. About psoriatic arthritis. Available at: https://www.psoriasis.org/about-psoriatic-arthritis Accessed: November 2023.
Creakyjoints. Psoriatic arthritis flare-ups. Available at: https://creakyjoints.org/living-with-arthritis/psoriatic-arthritis-flare-ups/ Accessed: November 2023.
NHS. Psoriatic arthritis. Available at: https://www.nhs.uk/conditions/psoriatic-arthritis/ Accessed: November 2023.
NHS. Psoriasis treatments. Available at: https://www.nhs.uk/conditions/psoriasis/treatment/ Accessed: November 2023
Lee MP et al. Arthritis Care Res 2018;70(5): 791-6.
NICE. Apremilast for treating active psoriatic arthritis. Available at: https://www.nice.org.uk/guidance/ta433 Accessed: November 2023
Versus Arthritis. Ciclosporin. Available at: https://www.versusarthritis.org/media/23512/ciclosporin-information-booklet-april2021.pdf Accessed: November 2023
AAD. Psoriatic arthritis treatment. Available at: https://www.aad.org/public/diseases/a-z/psoriatic-arthritis-treatment Accessed: November 2023
British Association of Dermatologists. Fumaric acid esters. Available at: https://www.bad.org.uk/pils/dimethyl-fumarate/ Accessed: November 2023
Ceglowska U, et al. Value in Health 2014: PSS6.
Arthritis Foundation. NSAIDs. Available at: https://www.arthritis.org/drug-guide/nsaids/nsaids Accessed: November 2023
NHS. Biological and biosimilar medicines. Available at: https://www.nhs.uk/conditions/biological-and-biosimilar-medicines/ Accessed: November 2023
National Psoriasis Foundation. Biologics. Available at: https://www.psoriasis.org/about-psoriasis/treatments/biologics Accessed: November 2023
British Association of Dermatologists. Guidelines for biologic therapy for psoriasis. 2017. Accessed: November 2023.
Verywell Health. Treating psoriatic arthritis with JAK inhibitors. Available at: https://www.verywellhealth.com/jak-inhibitors-psa-treatment-research-side-effects-4690551 Accessed: November 2023.
British Association of Dermatologists. Topical treatments for psoriasis. Available at: https://www.bad.org.uk/pils/psoriasis-topical-treatments/ Accessed: November 2023.
GP Notebook. Phototherapy in psoriasis. Available at: GP Notebook. Phototherapy in psoriasis. Available at: https://gpnotebook.com/simplepage.cfm?ID=1584070677 Accessed: November 2023.